Ipilimumab and Nivolumab in Leptomeningeal Metastases
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
- Status
- COMPLETED
- Phase
- PHASE2
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma
- Status
- COMPLETED
- Phase
- PHASE3
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
- Status
- COMPLETED
- Phase
- PHASE3
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
- Status
- COMPLETED
- Phase
- PHASE3
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE1
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2